The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Duodenal adenocarcinoma following a neuroendocrine tumor in the duodenum

  • Kim, Bun (Division of Gastroenterology, Department of Internal Medicine) ;
  • Huh, Ji Hye (Division of Gastroenterology, Department of Internal Medicine) ;
  • Kim, Youngsook (Division of Gastroenterology, Department of Internal Medicine) ;
  • Chung, Moon Jae (Division of Gastroenterology, Department of Internal Medicine) ;
  • Park, Jeong Youp (Division of Gastroenterology, Department of Internal Medicine) ;
  • Song, Si Young (Division of Gastroenterology, Department of Internal Medicine) ;
  • Park, Seung Woo (Division of Gastroenterology, Department of Internal Medicine)
  • Received : 2012.06.08
  • Accepted : 2012.12.03
  • Published : 2014.01.01
⟨ Previous Next ⟩

Abstract

Primary duodenal adenocarcinoma is a rare malignant neoplasm accounting for 0.3% of all gastrointestinal tract carcinomas. We herein present one case of duodenal adenocarcinoma after duodenal neuroendocrine carcinoma. Poorly differentiated duodenal neuroendocrine carcinoma with liver metastasis ($TxNxM_1$) was confirmed, and eight cycles of palliative chemotherapy (5-fluorouracil/etoposide/cisplatin) were administered. The patient was then in a clinically complete response status. About 1 year later, newly developed adenocarcinoma was detected at the same site. It was completely surgically resected, and the patient was cured.

Keywords

References

  1. Chow JS, Chen CC, Ahsan H, Neugut AI. A population-based study of the incidence of malignant small bowel tumours: SEER, 1973-1990. Int J Epidemiol 1996;25:722-728. https://doi.org/10.1093/ije/25.4.722
  2. Gabos S, Berkel J, Band P, Robson D, Whittaker H. Small bowel cancer in western Canada. Int J Epidemiol 1993;22:198-206. https://doi.org/10.1093/ije/22.2.198
  3. Lepage C, Bouvier AM, Manfredi S, Dancourt V, Faivre J. Incidence and management of primary malignant small bowel cancers: a well-defined French population study. Am J Gastroenterol 2006;101:2826-2832. https://doi.org/10.1111/j.1572-0241.2006.00854.x
  4. Rindi G, Capella C, Solcia E. Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract. Q J Nucl Med 2000;44:13-21.
  5. Scherubl H, Jensen RT, Cadiot G, Stolzel U, Kloppel G. Neuroendocrine tumors of the small bowels are on the rise: early aspects and management. World J Gastrointest Endosc 2010;2:325-334. https://doi.org/10.4253/wjge.v2.i10.325
  6. Nilsson O, Van Cutsem E, Delle Fave G, et al. Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology 2006;84:212-215. https://doi.org/10.1159/000098013
  7. Halfdanarson TR, McWilliams RR, Donohue JH, Quevedo JF. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg 2010;199:797-803. https://doi.org/10.1016/j.amjsurg.2009.05.037
  8. Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 2004;101:518-526. https://doi.org/10.1002/cncr.20404
  9. Zaanan A, Costes L, Gauthier M, et al. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol 2010;21:1786-1793. https://doi.org/10.1093/annonc/mdq038

Cited by

  1. Case of a tumor comprising gastric cancer and duodenal neuroendocrine tumor vol.22, pp.36, 2014, https://doi.org/10.3748/wjg.v22.i36.8242